CL AT 313 - Charleston Laboratories

Drug Profile

CL AT 313 - Charleston Laboratories

Alternative Names: CL-AT-313

Latest Information Update: 05 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Charleston Laboratories
  • Class Antitussives; Morphinans; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Common cold; Cough; Respiratory hypersensitivity

Most Recent Events

  • 05 Feb 2016 Phase-I clinical trials in Common cold in USA (PO)
  • 05 Feb 2016 Phase-I clinical trials in Cough in USA (PO)
  • 05 Feb 2016 Phase-I clinical trials in Respiratory hypersensitivity in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top